公开(公告)号：US20220412994A1

公开(公告)日：2022-12-29

申请号：US17775217

申请日：2020-11-06

Applicant: Randox Laboratories Ltd

Inventor： Paul Innocenzi ,  Mark Ruddock ,  John Lamont ,  Peter Fitzgerald

IPC: G01N33/68

Abstract: Described is the use of GFAP as a marker of drug-induced cellular toxicity and depression.

公开(公告)号：US20250003987A1

公开(公告)日：2025-01-02

申请号：US18707545

申请日：2022-11-08

Applicant: Randox Laboratories Ltd.

Inventor： Paul Innocenzi ,  Stephen Peter Fitzgerald ,  Ivan McConnell

IPC: G01N33/68 ,  G01N33/74

Abstract: A method is described for the identification of individuals with a BMI of less than 25 who have a biochemical profile that corresponds to an overweight or obese phenotype. The method of highlighting this hidden obesity makes use of various biomarker combinations that can incorporate various analytes including leptin and complement C3.

公开(公告)号：US20240003910A1

公开(公告)日：2024-01-04

申请号：US18037968

申请日：2021-11-15

Applicant: RANDOX LABORATORIES LTD

Inventor： Paul Innocenzi ,  Peter Fitzgerald ,  McMaster Steven

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N2800/7042

Abstract: Methods and products for adjusting the chronological age of a biological system or an individual to provide finer scale insight to health status are provided. The methods are underpinned by various serum and urinary biomarkers including antistreptolysin.